MilliporeSigma has accelerated plans to add a single-use assembly production unit at its site in Molsheim, France on the back of COVID-19 demand.
The $30 million injection at the site, just west of Strasbourg, will add 18,300 square feet of cleanroom space to produce MilliporeSigmaâ€™s Mobius single-use assemblies for use in the production of both COVID-19 vaccines and other therapies. The expansion will generate more than 350 jobs.
The facility will become the first European site to make the single-use offering and comes on the back of other single-use capacity expansions across MilliporeSigmaâ€™s production network.
â€śIn Molsheim, capacity will increase in several phases,â€ť MilliporeSigma spokeswoman Karen Tiano told BioProcess Insider. â€śBy the end of this year, we expect to add approximately five percent additional capacity. By mid-2023, when reaching full capacity, we expect to add approximately 50 percent additional capacity.â€ť
The firm recently began a $25 million investment at its site in Danvers, Massachusetts, to add 65,000 square feet of space for single-use assembly production. This, according to Tiano, has allowed the firm to double its production capacity.
â€śIn 2021, we anticipate moving from producing 300,000 single-use plastic assemblies to 600,000 assemblies used in the development and manufacturing of vaccines and other life-saving therapies.â€ť
The investments â€“ along with an expansion in Jaffray, New Hampshire, which makes single-use components and filtration equipment â€“ have been driven by the ongoing COVID-19 pandemic but were always on the cards.
â€śThis expansion was in the works for some time, but the pandemic accelerated our plans,â€ť according to Tiano.
Bioprocess vendors have been some of the beneficiaries of COVID-19 as demand for their equipment and consumables skyrockets as vaccines and therapies speed through the clinic. This is on the back of continued double-digit growth in the sector for the best part of a decade.
Thus, the acceleration of CAPEX plans by MilliporeSigma reflect others in the space. Cytiva, for example, has sped up $500 million of spending on the back of demand.